Barcelona Liver Bioservices enters into partnership with Novo Nordisk

[Barcelona, April 17th 2024] Barcelona Liver Bioservices (BLB) is pleased to announce a non-exclusive partnership with the global healthcare company Novo Nordisk aimed at characterizing the effects of novel chemical entities developed by Novo Nordisk for the treatment of chronic liver disease.

Chronic liver disease, along with its primary non-neoplastic complication, portal hypertension, stands as a significant global health challenge, marked by its high prevalence, leading cause of mortality, and economic burden. Despite these pressing concerns, safe and effective treatments remain elusive.

Under the terms of the agreement, BLB will leverage its diverse proprietary models of liver disease to explore the efficacy and underlying molecular mechanisms of Novo Nordisk’s best-in-class compounds, positioning them as potential treatments for chronic liver disease and portal hypertension.

Jordi Gracia-Sancho, Chief Scientific Officer at BLB, expressed enthusiasm about the collaboration: “Novo Nordisk has recognized the quality and usefulness of our pre-clinical solutions to accelerate the development of new therapeutics for liver diseases. We are keen on this new collaboration and the potential it holds to make a meaningful impact on liver disease management”.

This partnership represents a significant step forward in the quest to address the unmet medical needs of individuals suffering from chronic liver disease and portal hypertension. By combining expertise and resources, BLB and Novo Nordisk aim to bring innovative treatments closer to reality, offering hope to millions worldwide.

BLB provides valuable insights into complex disease pathways and drug responses in a more meaningful liver disease context. BLB specializes in in vivo, ex vivo and in vitro models of liver disease, including hepatic hemodynamics, histology, imaging, molecular biology, advanced cell culture systems and bioinformatics. For more information about the services and research developed by BLB please visit www.liver.barcelona

More News

Barcelona Liver Bioservices (BLB) starts operations

Barcelona Liver Bioservices (BLB), a spin-off of IDIBAPS, has been created for the design and development of pre-clinical studies in the fields of hepatology and hepatotoxicity. The co-founders are Jordi Gracia-Sancho, Jaume Bosch and Joan Carles Garcia-Pagan from IDIBAPS and Rosa Villa from CSIC.

Read More »